Dataset for "Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)"

1404 45 19887 2 81676 document 19887 Supplementary evidence file 1_Skeoch (1).xlsx application/vnd.openxmlformats-officedocument.spreadsheetml.sheet 81a0089d9d17533557f70a028dec055d MD5 422394 2026-02-12 14:17:19 https://researchdata.bath.ac.uk/1404/13/Supplementary%20evidence%20file%201_Skeoch%20%20%281%29.xlsx 1404 13 13 application/vnd.openxmlformats-officedocument.spreadsheetml.sheet other Medical and product codes used in CPRD GOLD within the work described in Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD). en public cc_by

Supplementary evidence file 1_Skeoch (1).xlsx

code 19888 2 81680 document 19888 Supplementary evidence file2.pdf application/pdf f3416626a0a7fb6fa89a7e864824025d MD5 639562 2026-02-12 14:19:46 https://researchdata.bath.ac.uk/1404/14/Supplementary%20evidence%20file2.pdf 1404 14 14 application/pdf other Further results for the study: Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD). en public cc_by

Supplementary evidence file2.pdf

data 19889 2 81684 document 19889 lightbox.jpg image/png 609c2ca1872f49567755a2d3630db3d5 MD5 20133 2026-02-12 14:55:43 https://researchdata.bath.ac.uk/1404/15/lightbox.jpg 1404 15 15 image/png other Thumbnails conversion from other to thumbnail_lightbox en public

lightbox.jpg

preview.jpg

medium.jpg

small.jpg

indexcodes.txt

http://eprints.org/relation/isVersionOf https://researchdata.bath.ac.uk/id/document/19888 http://eprints.org/relation/isVolatileVersionOf https://researchdata.bath.ac.uk/id/document/19888 http://eprints.org/relation/isIndexCodesVersionOf https://researchdata.bath.ac.uk/id/document/19888 archive 1951 disk0/00/00/14/04 2026-03-04 15:50:20 2026-03-07 05:56:05 2026-03-04 15:50:20 data_collection show Ellis Jessica je648@bath.ac.uk 0000-0002-9343-809X University of Bath FALSE McHugh Neil N.J.McHugh@bath.ac.uk 0000-0003-2765-658X University of Bath FALSE Pauling John J.D.Pauling@bath.ac.uk 0000-0002-2793-2364 University of Bath FALSE Bruce Ian N 0000-0003-3047-500X University of Manchester FALSE Charlton Rachel R.A.Charlton@bath.ac.uk 0000-0001-7360-2334 University of Bath FALSE McGrogan Anita A.McGrogan@bath.ac.uk 0000-0003-3855-9400 University of Bath TRUE Skeoch Sarah Sarah.Skeoch1@nhs.net 0000-0001-9015-7762 University of Bath FALSE Dataset for "Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)" GS0080 dept_pharm systemic lupus erythematosus, diagnosis, incidence, prevalence No coding included in these supplementary data files. Supplementary file 1 contains the medical and product codes using from the Clinical Practice Research Datalink in defining the population to be included in this study. Supplementary file 2 contains some further results and information about the cohort that were not included in the main publication but may be useful to aid understanding of the results found. 2024-07-27 University of Bath public RightsHolder University of Bath RightsHolder Clinical Practice Research Datalink University of Bath https://doi.org/10.13039/501100000835 Methods are described in full in the paper. Briefly: * SLE Read codes, were identified from the CPRD dictionary and from review of code lists reported in previous CPRD studies. * Code lists were reviewed independently by two rheumatologists and those with agreement retained. * Clinical and immunological features suggestive of SLE based on the 2019 EULAR-ACR classification criteria were found. * Immunosuppressants were amended to include SLE related medications which are now more widely used (addition of Leflunomide, Mycophenolate Mofetil, Rituximab and Tacrolimus and Belimumab). * Test data (e.g. white cell count) had inclusion thresholds set based on unit types and expected normal values. The cohort was selected as described in the case ascertainment section of the paper. Data was aggregated and described in the paper. No changes to the original data that we received (already deidentified) were made. SQL Developer was used to process the raw data; analysis was carried out using R. en 1 10.15125/BATH-01404 https://doi.org/10.48329/yycw-n139 data https://doi.org/10.1136/lupus-2024-001213 pub open